Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: iPSCs-derived CAR NK therapies - Cytovia Therapeutics/New York Stem Cell Foundation

Next Previous
Drug Profile

Research programme: iPSCs-derived CAR NK therapies - Cytovia Therapeutics/New York Stem Cell Foundation

Alternative Names: GPC3 CAR NK cell therapies; Induced pluripotent stem cells-derived chimeric antigen receptor natural killer cell therapies - Cytovia Therapeutics/The New York Stem Cell Foundation; Research programme: iPSCs-derived CAR NK therapies - Cytovia Therapeutics/The New York Stem Cell Foundation

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytovia Therapeutics; The New York Stem Cell Foundation
  • Class CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 05 Oct 2020 Preclinical trials in Cancer in USA (Parenteral) before October 2020 (Cytovia Therapeutics pipeline, October 2020)
  • 25 Aug 2020 Cytovia Therapeutics and the New York Stem Cell Foundation Research institute plans to file patents on the engineering, expansion and Good Manufacturing Practices manufacturing processes of induced pluripotent stem cells natural killer cells to treat cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top